Although inhibitors of the downstream effectors such as RAF and MEK exhibit good therapeutic efficacies in BRAF mutant melanoma cells [9, 15], most cancer cells are resistant to the single inhibitor treatments [16–20]. This evidence concerns the gene BRAF and cancer.